Zealand Pharma begins Phase 3 ZUPREME programme for petrelintide in obesity
Zealand Pharma and Roche have started the global Phase 3 ZUPREME programme evaluating once-weekly petrelintide as a treatment for people with overweight or obesity.
The registrational programme includes three Phase 3a studies expected to enrol around 7,000 participants across populations with obesity, type 2 diabetes and cardiovascular disease.
The move into Phase 3 represents a major development milestone for the amylin analogue and positions petrelintide as a potential future competitor in the rapidly expanding obesity-treatment market.
Field | Content |
Alert Type | Industry Update |
Companies | Zealand Pharma; Roche |
Development Type | Phase 3 programme initiation |
Drug Candidate | Petrelintide |
Programme | ZUPREME |
Therapy Area(s) | Obesity; metabolic disease; type 2 diabetes; cardiovascular disease |
Technology or Modality | Long-acting amylin analogue |
Development Stage | Registrational Phase 3a |
Planned Enrollment | Approximately 7,000 participants across three trials |
Geography | Global |
What Happened | Zealand Pharma and Roche initiated the global registrational Phase 3 ZUPREME programme for once-weekly petrelintide in chronic weight management. |
Why It Matters | Progression into Phase 3 moves petrelintide substantially closer to potential regulatory submission and commercial competition in obesity treatment. |
Supporting Context | The programme is designed to evaluate petrelintide across obesity populations both with and without type 2 diabetes and cardiovascular disease. |
Potential Impact | If successful, petrelintide could add a new amylin-based therapeutic option to a market currently dominated by incretin-based medicines. |
Key Takeaway | Petrelintide has entered a large global Phase 3 programme involving around 7,000 participants. |
What to Watch | Weight-loss efficacy, tolerability, cardiovascular outcomes and timing of regulatory submissions. |
Primary Source | Zealand Pharma |
Relevant Date | 22 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
コメント